Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Idera Pharmaceuticals Inc (IDRA) a Good Stock to Buy?

Page 1 of 2

Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly interesting group of stocks that hedge funds like is the small-caps. The huge amount of capital does not allow hedge funds to invest a lot in small-caps, but our research showed that their most popular small-cap ideas are less efficiently priced and generate stronger returns than their large- and mega-cap picks and the broader market. That is why we follow the hedge fund activity in the small-cap space.

Is Idera Pharmaceuticals Inc (NASDAQ:IDRA) ready to rally soon? Money managers are categorically getting more optimistic. The number of bullish hedge fund positions rose by 2 in recent months. IDRAwas in 9 hedge funds’ portfolios at the end of the third quarter of 2016. There were 7 hedge funds in our database with IDRA positions at the end of the previous quarter. At the end of this article we will also compare IDRA to other stocks including Reading International, Inc. (NASDAQ:RDI), Aralez Pharmaceuticals Inc (NASDAQ:ARLZ), and City Office REIT Inc (NYSE:CIO) to get a better sense of its popularity.

We follow over 700 hedge funds and other institutional investors and by analyzing their quarterly 13F filings, we identify stocks that they are collectively bullish on and develop investment strategies based on this data. One strategy that outperformed the market over the last year involves selecting the 100 best-performing funds and identifying the 30 mid-cap stocks that they are collectively most bullish on. Over the past year, this strategy generated returns of 18%, topping the 8% gain registered by S&P 500 ETFs. We launched this strategy 2.5 years ago and it returned more than 39% since then, vs. 22% gain registered by the S&P 500 ETFs.

researcher, research, background, medical, health, test, chemistry, experiment, equations, technician, table, reaction, pharmaceutical, periodic, liquid, dropper, tool, bio, discovery

SUWIT NGAOKAEW/Shutterstock.com

Now, let’s take a look at the fresh action surrounding Idera Pharmaceuticals Inc (NASDAQ:IDRA).

Hedge fund activity in Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Heading into the fourth quarter of 2016, a total of 9 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of 29% from the second quarter of 2016. By comparison, 15 hedge funds held shares or bullish call options in IDRA heading into this year. So, let’s review which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

HedgeFundSentimentChart

According to Insider Monkey’s hedge fund database, Julian Baker and Felix Baker’s Baker Bros. Advisors has the number one position in Idera Pharmaceuticals Inc (NASDAQ:IDRA), worth close to $18 million. The second largest stake is held by Kevin Kotler of Broadfin Capital, with a $6.2 million position. Remaining peers with similar optimism consist of William Leland Edwards’s Palo Alto Investors, Anand Parekh’s Alyeska Investment Group and Israel Englander’s Millennium Management which is one of the 10 largest hedge funds in the world. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds which is based on the performance of their 13F long positions in non-microcap stocks.

Page 1 of 2